Heart Calcium CT Scans: What They Are—and Why Medicare Doesn’t Fully Cover Them

In an era where early detection is increasingly seen as the key to better health outcomes, one test has quietly gained attention among cardiologists and informed patients alike: the heart calcium CT scan. Also known as a coronary artery calcium (CAC) scan, it promises a clearer picture of cardiovascular risk—often before symptoms appear.

Yet despite its clinical value, the scan is not fully covered by Medicare in Australia, leaving many patients to pay out of pocket. Why?

What Is a Heart Calcium CT Scan?

A heart calcium CT scan is a specialised imaging test that uses computed tomography (CT) to detect calcium deposits in the coronary arteries—the vessels that supply blood to the heart muscle.

These calcium deposits are not benign. They are a marker of atherosclerosis, the process that leads to coronary artery disease, heart attacks, and, ultimately, death in severe cases.

How It Works

• The scan is non-invasive.

• No contrast dye is typically required.

• The procedure takes around 10–15 minutes.

• Radiation exposure is relatively low, though not negligible.

The result is expressed as a calcium score:

• 0: No detectable plaque—low risk.

• 1–100: Mild plaque—moderate risk.

• 101–400: Significant plaque—elevated risk.

• 400+: Extensive plaque—high risk of cardiovascular events.

In simple terms, the higher the score, the greater the burden of coronary artery disease.

Why It Matters

Traditional cardiovascular risk assessment relies on factors such as:

• Age

• Blood pressure

• Cholesterol levels

• Smoking status

• Diabetes

While useful, these are indirect indicators. A calcium CT scan, by contrast, provides direct evidence of disease.

The Clinical Advantage

• Identifies hidden risk in people who appear healthy.

• Helps refine treatment decisions (e.g., whether to start statins).

• Can reassure low-risk individuals and avoid unnecessary medication.

For many clinicians, the CAC scan represents a shift from probabilistic risk to visual, measurable disease burden.

Who Should Consider It?

The scan is generally most useful for:

• People aged 40–70 with intermediate risk of heart disease.

• Patients with a family history of early heart attacks.

• Individuals with borderline cholesterol or blood pressure results.

• Those seeking more certainty before committing to long-term medication.

It is less useful for:

• Very low-risk individuals (where results are unlikely to change management).

• High-risk patients (who already require aggressive treatment regardless of score).

The Cost Question: Why Isn’t It Fully Covered?

In Australia, Medicare does not routinely provide full coverage for coronary calcium scans. Patients typically pay between $100 and $300 out of pocket, depending on the provider.

The reasons are not purely financial—they are grounded in policy, evidence thresholds, and system design.

1. Evidence vs Policy Thresholds

While there is strong international evidence supporting CAC scoring, Medicare funding decisions require:

• Clear demonstration that a test improves outcomes at a population level.

• Evidence that it changes management in a cost-effective way.

The issue is not whether the scan is useful—it is whether it meets the strict criteria for universal subsidisation.

Policy makers tend to ask:

• Does widespread use reduce heart attacks and hospitalisations?

• Does it justify the cost across millions of Australians?

The answers, while promising, are still debated in policy circles.

2. Preventive vs Reactive Healthcare

Australia’s Medicare system has historically been more focused on:

• Diagnosing and treating existing illness.

• Funding procedures with immediate clinical necessity.

Preventive tools—especially those used in asymptomatic individuals—often struggle to gain full coverage.

A calcium scan sits squarely in the preventive category:

• It identifies risk before symptoms.

• It may lead to earlier intervention—but not immediate treatment.

This places it in a grey zone within the funding framework.

3. Risk of Overuse

Another concern is overutilisation.

If fully subsidised, there is a risk that:

• Low-risk individuals may undergo unnecessary scans.

• Incidental findings could lead to further testing, increasing costs.

• Health system resources could be diverted from higher-priority needs.

Medicare aims to balance access with appropriate use—sometimes erring on the side of restriction.

4. Radiation Considerations

Although the radiation dose is relatively low, it is not zero.

From a public health perspective:

• Widespread screening of low-risk populations raises cumulative exposure concerns.

• Funding decisions often factor in long-term population-level risks.

5. Budget Constraints and Prioritisation

Healthcare funding is finite. Medicare must prioritise:

• Life-saving treatments.

• Essential diagnostics.

• High-impact interventions.

Even a modest-cost test, when scaled across millions of people, represents a significant budget commitment.

The question becomes not just “Is this useful?” but “Is this the best use of limited resources?”

The International Context

In countries like the United States, CAC scans are widely available but often not covered by insurance. Patients typically pay out of pocket, similar to Australia.

This reflects a global pattern:

• Strong clinical interest.

• Growing use in targeted populations.

• Limited universal funding.

Should It Be Covered?

There is a growing argument that Medicare should expand coverage—at least for specific groups.

The Case For Coverage

• Early detection could reduce heart attacks and hospital admissions.

• Targeted use in intermediate-risk patients is highly effective.

• It empowers patients to make informed decisions about prevention.

The Case Against

• Risk of overuse and unnecessary follow-up testing.

• Unclear cost-effectiveness at a population level.

• Competing priorities within the health budget.

A middle ground may emerge:

• Targeted subsidies for defined risk groups.

• GP referral criteria to ensure appropriate use.

• Integration into broader cardiovascular prevention strategies.

The Bottom Line

The heart calcium CT scan is a powerful diagnostic tool that provides a direct window into coronary artery disease—often before symptoms arise. It represents a shift toward proactive, personalised medicine.

Yet its partial exclusion from full Medicare coverage reflects deeper tensions in the healthcare system:

• Prevention versus treatment.

• Individual benefit versus population cost.

• Clinical innovation versus policy conservatism.

For now, Australians who want the clarity a calcium score can provide will likely need to contribute financially. Whether that changes will depend on evolving evidence, policy priorities, and the broader push toward preventive healthcare.

In the meantime, the scan remains what it has always been: not essential for everyone—but potentially invaluable for the right patient at the right time.